SUTRO
Live / Registered — Registered (as of 21 Jul 2026)
What this means for you
Registered since 21 Jul 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 21 Jul 2032: the §8 declaration of use).
Record
- Serial number
- 98694731
- Registration number
- 8357229
- Mark type
- Word mark
- Filed
- 12 Aug 2024
- Published for opposition
- 27 May 2025
- Registered
- 21 Jul 2026
- Next maintenance filing
- §8 declaration of use, due by 21 Jul 2032 (grace period to 21 Jan 2033)
- Attorney of record
- Karen Won
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for the immune system targeting immuno-oncology pathways; Pharmaceutical and biological preparations for use in oncology; Pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; Therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, dual conjugates, cytokines, bispecific antibodies, and engineered antibodies for destroying tumor cells and stimulating immune response; Vaccines; Bacterial lysate preparations and bacterial extract preparations, for use in the cell free production of therapeutic proteins and peptides for medical use
- Class 040 — Treatment of materials: Custom manufacturing of pharmaceuticals and therapeutic agents for medical use; Custom manufacturing of bacterial lysate preparations and bacterial extract preparations.
- Class 042 — Scientific and technological services: Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, dual conjugates, cytokines, bispecific antibodies, engineered antibodies, oncology, and immunology; Providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, cytokines, bispecific antibodies, engineered antibodies, oncology, and immunology; Drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases.
Owner
- Sutro Biopharma, Inc., South San Francisco, CA, US
- Sutro Biopharma, Inc., South San Francisco, CA, US
- Sutro Biopharma, Inc., South San Francisco, CA, US
Prosecution history
- 21 Jul 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 Jul 2026 — REGISTERED-PRINCIPAL REGISTER
- 30 Jun 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 30 Jun 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 09 Jun 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 24 Feb 2026 — USE AMENDMENT FILED
- 09 Jun 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 25 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Feb 2026 — TEAS STATEMENT OF USE RECEIVED
- 24 Feb 2026 — SOU EXTENSION 2 GRANTED
- 24 Feb 2026 — SOU EXTENSION 2 FILED
- 24 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 17 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Jan 2026 — SOU EXTENSION 1 GRANTED
- 16 Jan 2026 — SOU EXTENSION 1 FILED